Skip to main content

Notice for tocilizumab (Roche Products Pty Limited)

Active ingredients
Date of review outcome
Lapse date
Provisional approval
Coronavirus disease 2019 (COVID-19) (IV formulation only) for the treatment of coronavirus disease 2019 (COVID-19) in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation
Therapeutic area
Infectious diseases

Help us improve the Therapeutic Goods Administration site